PAREXEL Chairman and CEO Josef von Rickenbach Elected 2013 ACRO Chairman
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that its Chairman and CEO, Josef von Rickenbach, has been named 2013 chairman of the Association of Clinical Research Organizations (ACRO).
Since its founding in 2002, ACRO has been committed to highlighting CRO expertise in all aspects of the clinical research enterprise. ACRO represents the CRO industry globally to pharmaceutical, biotech and medical device companies, regulators and legislators, peer associations, academic organizations, patient groups, the media and the public.
“It is an honor to have been selected to lead ACRO’s Board of Directors in 2013,” said Mr. von Rickenbach. “As incoming chairman, I look forward to continuing the great momentum initiated by my predecessor to help ACRO and its members build and strengthen public understanding and confidence in clinical research. Equally, I welcome the opportunity to collaborate with the association’s global stakeholders to promote the strategic value of clinical outsourcing, drive innovation in the drug development process and ensure the safe and ethical development of new medicines and treatments.”
Mr. von Rickenbach has taken PAREXEL from pioneering beginnings as one of the first clinical research organizations in the early 1980s to its place today as one of the top three public biopharmaceutical services providers. As Chairman and CEO of PAREXEL, he was one of the first to define the clinical research services sector. To make clinical development more effective for clients, he conceived a multidisciplinary and systems-oriented approach to outsourced clinical development, bringing efficiencies, scalability, and standardization to the process.
Mr. von Rickenbach previously served as Chair of ACRO in 2005 and is a long-standing member of the ACRO Board of Directors. He also serves on the Board of Directors of the New England Healthcare Institute. He holds a B.S. degree in Business Economics from the School of Business at the Lucerne University of Applied Sciences in Switzerland, and a Master of Business Administration degree from Harvard Business School.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
